Bafna Pharmaceuticals Limited

NSE BAFNAPH.NS

Bafna Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2024: 9.60%

Bafna Pharmaceuticals Limited EBITDA Margin is 9.60% for the year ending March 31, 2024, a -41.69% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Bafna Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2023 was 16.46%, a 21.84% change year over year.
Bafna Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2022 was 13.51%, a -9.43% change year over year.
Bafna Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2021 was 14.92%, a 355.94% change year over year.
Bafna Pharmaceuticals Limited EBITDA Margin for the year ending March 31, 2020 was 3.27%, a 111.18% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NSE: BAFNAPH.NS

Bafna Pharmaceuticals Limited

CEO	Mr. Bansilal Mahaveer Chand Bafna
IPO Date	Nov. 12, 2012
Location	India
Headquarters	Bafna Towers
Employees	363
Sector	Healthcare
Industries Pharmaceuticals 3D Printing Cleaning Supplies Composite Materials Cosmetics Drugstores & Retail Pharmacies Glass Plastics

Description

Bafna Pharmaceuticals Limited manufactures and sells finished pharmaceutical formulations in India. The company provides delayed and sustained release, chewable, and orally disintegrating tablets. It also exports its products. Bafna Pharmaceuticals Limited was founded in 1981 and is based in Chennai, India.

Key trends

Past 5 years